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ABSTRACT 
Vesicular Stomatitis Virus (VSV) is a good candidate for oncolytic therapy due to its ability to 
induce apoptosis in a number of different types of cells. VSV's effect on macrophages has not 
been studied in-depth. Here, the effects of infection with both wild type (rwt) VSV  and matrix 
(M) protein mutant (rM51R-M) VSV on cytokine production and cell viability of M2 
macrophages cultured  alone and in co-culture with MDA-MB-231 breast cancer cells were 
studied. Infection with rM51R-M VSV induced an increase in pro-inflammatory cytokines IL-6 
production in co-culture conditions and TNF-α by M2 macrophages cultured alone. Viability of 
M2 macrophages cultured alone decreased after infection with both types of VSV. In co-culture 
conditions, cell viability decreased after infection with rwt VSV and increased after infection 
with rM51R-M VSV. We also set out to determine whether the MDA-MB-231 breast cancer 
cells or THP-1 monocytes were better labeled with fluorescent dye. Cancer cells were more 
readily labeled than monocytes. Working concentrations of dye were tested but an adequate 
concentration was not determined. Our data suggests that rM5R-M VSV can both modulate M2 
macrophage phenotypes to a more M1-like phenotype and kill breast cancer cells, making it a 
suitable candidate for oncolytic therapy. 
 
INTRODUCTION 
Breast Cancer  
Breast cancer is the second most commonly diagnosed cancer among women, with about 
1 in 8 women being diagnosed with invasive breast cancer in her lifetime. Approximately 80% of 
breast cancer diagnoses are invasive ductal carcinoma, and the 5-year survival rate of women 
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with Stage IV metastatic cancer is estimated to be as low as 22% ("U.S. Breast Cancer 
Statistics", Breastcancer.org). Current treatments for these invasive types of breast cancer are 
highly ineffective (Chung & Carlson, 2003). Current treatment options for those suffering with 
invasive breast cancer include radiation, surgery, and chemotherapy. Radiation and surgery are 
more localized treatment options, focusing more on the eradication and removal of the primary 
tumor. Chemotherapy is a systemic treatment that affects all of the cells in the body of the 
patient, and often elicits many negative side effects including nausea, fatigue, and hair loss. 
Radiation and surgery are ineffective treatments for invasive breast cancer due to their inability 
to target sites of distant metastasis. Chemotherapy has more promise as a treatment for invasive 
breast cancer due to its systemic effects, however it has been shown that chemotherapy is only 
moderately effective in treating metastatic breast cancer, however does not eradicate all the 
cancer from the body. It can also be damaging to the patient's body, such that the patient's quality 
of life decreases as a result of chemotherapy's harmful side effects (O’Shaughnessy, 2005). 
Therefore, there is critical need for the development of alternative and more effective treatment 
options for the treatment of cancer, especially metastatic disease.  
 
Metastatic Cancer 
Cancer is considered to be metastatic when it migrates from the primary tumor into a 
distant location in the body (Seyfried and Huysentruyt, 2013). To metastasize, all potential 
secondary tumors must first invade, disseminate, and subsequently colonize a distal environment. 
The biological events are orchestrated through intrinsic and extrinsic homeostatic factors and 
molecular pathways. The invasion–metastasis cascade begins with neovascularization, the 
transition from epithelial to mesenchymal subtype, and the breakdown of extracellular matrix 
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and basement membrane. These events increase potent angiogenic factors, such as platelet-
derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), increasing 
tumorigenicity. The degradation of the basement membrane is facilitated by matrix 
metalloproteinases (MMPs). In breast cancer, deregulation of MMP expression, especially 
MMP-2 and MMP-9, promotes invasion and metastasis. MMP-mediated degradation of the 
extracellular matrix releases numerous growth factors and signaling molecules that enable tumor 
expansion. In addition, the tumor microenvironment (TME) cancer cells find themselves in also 
contributes greatly to numerous aspects of tumorigenicity, including metastasis. Cancer cells 
interact with surrounding fibroblast, stromal, immune, and endothelial cells through factors that 
promote angiogenesis, membrane degradation, epithelial–mesenchymal transition (EMT), and 
colonization.  
Once cancer has metastasized and colonized distant tissues, it becomes much more 
difficult to treat, such that 90% of cancer fatalities occur as a result of cancer metastasis in the 
body (Seyfried and Huysentruyt, 2013). Currently, most chemotherapeutic approaches revolve 
around obstructing established tumors through a combination of surgical resection and adjuvant 
therapy. These therapies have positive outcomes for breast cancer patients with exclusively 
primary tumors; however, metastatic cancer, being systemic in nature and resistant to 
chemotherapeutics, tends to have poorer prognosis. Therefore, understanding the factors that 
contribute to metastasis are critical for developing effective therapeutics. For my studies, I am 
interested in investigating the interaction between breast cancer cells and tumor-associated 
macrophages (TAMs) and how therapies targeting this interaction may modify the course of 
disease. 
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Oncolytic Viral Therapies 
One therapy that has been proposed to treat metastatic breast cancer is oncolytic viral therapy. 
Oncolytic viruses selectively replicate in and kill cancer cells without harming healthy cells (Liu 
et. al., 2003; Balachandran & Barber, 2000). The basis for oncolytic therapies is that cancer cells 
frequently develop alterations in their immune response components, including the type I 
interferon (IFN) antiviral response pathway during the process of tumorigenesis. Therefore, 
cancer cells allow high levels of virus replication resulting in induction of cell death pathways, 
while normal cells with intact antiviral responses are spared from virus-induced cytopathology. 
In addition to the natural ability of viruses to kill cancer cells, oncolytic viruses are also being 
engineered to selectively kill cancer cells over normal cells. There have been promising results 
from clinical trials in which numerous oncolytic viruses are being used as a therapeutic agents 
for the treatment of a variety of cancers.  For example, an E1B 55 kD gene deleted strain of 
adenovirus, known as H101, was approved for the treatment of head and neck cancer in China in 
2005 in combination with chemotherapy. More recently, T-Vec (talimogene laherparepvec), a 
second-generation oncolytic modified herpes simplex virus (HSV) that has been engineered to 
express human granulocyte-macrophage colony-stimulating factor (GM-CSF), was approved as a 
treatment for melanoma in the US in 2015 (Fukuhara et. al., 2015).  Although strides have been 
made in the approval of such agents for the treatment of cancers, progress in terms of widespread 
usage has been slow due to multiple limiting factors, including lack of expertise with 
intratumoral viral injections by oncologists and preference for more familiar cancer therapeutics 
over viral therapies (Rehman, 2016). 
 In addition to being used as individual therapeutic agents for cancer treatment, it has also 
been proposed to use oncolytic viruses in conjunction with other anti-tumor agents as 
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combination therapies. Studies in specific tumor models have shown that cancer-specific factors 
may render the tumor resistant to oncolytic therapies alone. Therefore synergistic combination 
approaches may be necessary to enhance the oncolytic effects of different viruses. For example, 
one study found that for the treatment of malignant gliomas, adding rapamycin, an 
immunosuppressant, significantly enhanced the replication of oncolytic poxvirus by suppressing 
the immune response to the virus. (Lun, 2009). Another study combined a prostate-targeted 
herpes simplex virus type 1 (HSV-1) with a taxane drug and observed reduced tumor grown in 
vivo. This study also found that the combination therapy induced synergistic cytotoxicity of 
prostate cancer cells, due to both the HSV-1 and the taxane's abilities to arrest cells in certain 
stages of the cell cycle, thereby inducing eventual cell death (Passer et. al., 2009). Therefore, it is 
increasingly being appreciated that specific combination approaches may be more efficacious 
than single therapies alone. 
 
Vesicular Stomatitis Virus 
One virus currently being studied for use as an oncolytic agent is vesicular stomatitis 
virus (VSV). VSV, an enveloped virus in the family Rhabdoviridae, has a negative single-
stranded mRNA genome. It is pathogenic to cattle, with infection producing lesions and sores in 
the mouths and on the hooves of cows (Ahmed & Lyles, 1998). However, VSV is typically 
nonpathogenic in humans, exhibiting flu-like syndromes in rare cases (Ahmed & Lyles, 1998). 
VSV is a good candidate as an oncolytic agent due to its ability to induce apoptosis in numerous 
types of cancer cells. The virus enters cells with the help of clathrin-coated vesicles and is able to 
replicate in a wide variety of cell types. In the process of virus replication, the wild type (wt) 
strain of the virus inhibits the host IFN antiviral response through the function of the viral matrix 
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(M) protein, which prevents the host cell from transcribing the products necessary to recognize 
and defend against it. Specifically, studies have shown that M protein of VSV inhibits new host 
gene expression through inhibition of host transcription and nuclear-cytoplasmic transport of 
host messages, with the effect of inhibiting the expression of antiviral gene products (Ahmed et. 
al, 2003). 
rM51R-M virus is a M protein mutant strain of VSV that has a methionine to arginine 
switch at amino acid 51 of the M protein. This mutation renders the virus defective in inhibiting 
host gene expression, thus allowing the host cell to mount an IFN response and express gene 
products with antiviral activity. Previous studies have highlighted the selectivity of M protein 
mutant viruses as selective oncolytic agents with the ability to induce innate immune responses. 
In one study, virus was more quickly cleared from the nasal mucosa of mice that were inoculated 
with rM51R-M VSV when compared to mice that were inoculated with rwt VSV. The mutant 
strain of VSV was also unable to spread to the central nervous systems of the mice, unlike rwt 
VSV (Ahmed et. al., 2008), thus demonstrating its safety in vivo. In addition to being a safer 
oncolytic agent than wild-type strains of VSV, rM51R-M virus has also been shown to exhibit 
immunostimulatory properties. One study found that rM51R-M virus was able to induce 
maturation of myeloid dendritic cells after infection through stimulating IFN expression and 
expression of cytokines involved in dendritic cell maturation. Additionally, the dendritic cells 
that matured through infection with rM51R-M virus were found to be competent in priming T-
cells, such that they proliferated more robustly and had greater effector function than T-cells 
primed with lipopolysaccharide, a bacterial endotoxin (Ahmed et. al, 2006). Its ability to induce 
an immunostimulatory response and the fact that it is safer than wt VSV make rM51R-M VSV a 
good candidate as an oncolytic agent.  
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As mentioned previously, my study involves investigating the effects of VSV on breast 
cancer. The breast cancer cells we utilize for our studies (MDA-MB-231 cells) have defects in 
their IFN response pathway, thus they are unable to respond or defend themselves against viral 
infection. As a result of their inability mount an effective antiviral response, the virus is able to 
replicate within the cancer cells, induce apoptotic and other cell death mechanisms, and spread to 
neighboring cells. The viral progeny are thus equipped to infect and lyse other cancer cells in the 
tumor mass. In addition to releasing viral progeny, a main component of oncolytic therapies is 
the ability of viruses to kill cancer cells to release tumor antigens that can be sampled and 
identified by infiltrating immune cells. This creates a cancer-specific immunogenic response to 
promote the targeting and killing of cancer cells not only at the primary tumor site, but at 
metastatic distal sites. 
         One immune cell type that samples antigens in the environment for processing and 
presenting is the macrophage. Macrophages are phagocytic lymphocytes found both in bodily 
tissues and in the bloodstream in the form of white blood cells. They are derived from 
monocytes, which are found in the blood and polarize into macrophages after exposure to certain 
cellular products and cytokines. There are numerous types of macrophages in the body, with the 
M1 and M2 types being the main focus of my project. M1 macrophages are pro-inflammatory 
and are responsible for defending against intracellular pathogens as well as cancers. M2 
macrophages have an anti-inflammatory function and are primarily responsible for wound 
healing and protecting the body from extracellular pathogens such as parasites (Chávez-Galán et 
al., 2015). Along with other immune cell types, macrophages are a main component of the tumor 
microenvironment. Macrophages found within the primary tumor are known as tumor-associated 
macrophages (TAMs). A large number of M1 macrophages in the tumor microenvironment is 
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correlated to a better prognosis amongst invasive triple-negative breast cancer patients, while a 
high number of M2 macrophages in the tumor microenvironment is correlated with a poor 
prognosis. Therefore, targeting M2 macrophages within the tumor microenvironment is currently 
a focus for numerous types of cancer therapeutics. 
TAMs play an important role in the tumor microenvironment. During early tumor 
progression, M1-polarized macrophages have high tumoricidal activity and work to aid the 
immune system in disrupting tumor activity and growth. However, during late-stage tumor 
progression, macrophages are induced into an M2-like phenotype. M2 macrophages have several 
functions within the tumor microenvironment, such that they aid the advancement of tumor 
progression. M2-like TAMs assist in angiogenesis of vasculature into the tumor and 
immunosuppression of cells around the tumor (Chanmee et al., 2014). M2 macrophages also play 
a role in the metastasis of cancer and the migration of cancer cells from the primary tumor to 
distant sites in the body. They do this by forming a complex that includes the M2 macrophage, a 
cancer cell, and an endothelial cell. This complex is able to extravasate through the blood vessel 
wall and migrate to distant tissues in the body, including the liver and the lungs. Therefore, M2 
macrophages represent a target for therapeutics due to their contributions in tumorigenesis. 
Current therapeutics are focused on eliminating or converting M2 macrophages to a more 
inflammatory macrophage phenotype with anti-cancer properties, such as M1 macrophages.  
Previous research in our laboratory suggests that, when infected with oncolytic VSV, M2 
macrophages can be educated to convert to an M1-like phenotype, perhaps through induction of 
the type I IFN response by rM51R-M virus (Polzin, 2017). However, it is unknown how M2 
macrophages will respond to VSV in the context of a tumor microenvironment. M1 macrophages 
secrete pro-inflammatory cytokines, including IL-6 and TNF-alpha, whereas M2 macrophages 
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secrete anti-inflammatory cytokines, including TGF-beta and IL-10. (Carswell et. al., 1975) 
Therefore, the production of specific cytokines in culture is indicative of the ability of 
macrophages to undergo phenotypic switching in response to therapies. 
The overall goal of my project is to determine the effect of therapies with oncolytic VSV 
on M2 macrophages and breast cancer cells in a simulated tumor microenvironment. For these 
studies, THP-1 cells differentiated to M2 macrophages were co-cultured with MDA-MB-231 
breast cancer cells and infected with a wild-type (wt) strain of VSV, rwt virus, as well the M 
protein mutant virus, rM51R-M virus. Cytokine secretion and cell viability was determined 
following infection as an indication of these cell populations to respond to the different VSV 
strains. Rwt virus, containing the wt M protein, is a potent inhibitor of host gene expression, 
while the M protein mutant virus is defective at this function and thus, allows the expression of 
genes in infected cells including those involved in inducing an antiviral response. I hypothesize 
that upon infection with VSV, the secretion of cytokines IL-6 and TNF-α will be upregulated in 
samples containing M2 macrophages alone and co-culture samples. This result may be more 
prominent in cells infected with rM51R-M virus due to its ability to induce innate immune 
responses. I also hypothesize that, in co-culture, M2 macrophages and breast cancer cells will be 
more resistant to cell death induced by infection with VSV. In addition, I predict that cells will 
be more sensitive to killing by the wt strain of VSV, rwt virus, due to its ability to suppress the 
host antiviral response. Our results showed that infection with rM51R-M virus induced an 
upregulation of inflammatory cytokine production both in samples containing M2 macrophages 
alone as well as in co-culture samples. Results also indicated that rwt VSV is more cytotoxic to 
cells than mutant virus, and that cells are more resistant to both strains of VSV in co-culture 
when compared to the macrophages alone. Therefore, we can conclude that the rM51R-M virus 
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may be able to induce a phenotypic switch in M2 macrophages to a more M1-like phenotype, 
and that the mutant VSV is a promising agent for oncolytic virotherapy.  
 
 
METHODS 
Cell lines and viruses 
The MDA-MB-231 breast cancer cells were obtained from the laboratory of Dr. Darren Seals. 
They were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) in 
100mm plates and incubated at 37°C + 5% CO2. The THP-1 human monocytic cell line was 
cultured at a baseline concentration of 200,000 cells/mL in RPMI containing antibiotics and 
supplements (100x vitamins, 5 mL Penn/Strep, 5 mL of 1 M Hepes, 1.75 µL 2-mercaptoethanol, 
50 mL FBS) and incubated at 37°C + 5% CO2. Recombinant wild-type (rwt) virus and the matrix 
(M) protein mutant (rM51R-M) virus were generous gifts from Dr. Doulas Lyles from Wake 
Forest University Baptist Medical Center (Winston-Salem, NC) and have been described 
previously (Whitlow et al., 2006). Virus stocks were prepared in BHK cells using methods 
described previously  (Kopecky et al., 2001). Specifically, BHK cells were grown in 6-well 
plates and infected with virus stock at different dilutions. At 1 hour, sterile 2X Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 2% FBS was added in equal parts to 2% 
agar and added to the cells. Following 24-48 hours of incubation, plates were refrigerated for one 
hour following the addition of 3.7% formaldehyde to each well. Formaldehyde and agar was 
removed, and crystal violet was added to each well for visualization of plaque formation and 
quantitation of viral titers in PFU (plaque forming units)/ml. 
 
Monocyte polarization to M2 macrophage phenotype 
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THP-1 monocytes were placed in 24-well plates at a concentration of 500,000 cells/mL of media, 
such that there were 500,000 cells in each well. Phorbol myristate acetate (PMA) was added to 
each well at a concentration of 1μL/mL and the cells were left to polarize into M0 macrophages 
for 24 hours. After 24 hours, the cells were examined to ensure that they had “settled” onto the 
bottom of the plate. After polarization to M0 macrophages, the old media was pulled off. 
Interleukin-4 (IL-4), Interleukin-13 (IL-13), PMA, and RPMI were combined in a test tube at a 
concentration of 1 μL of cytokines per 1 mL of RPMI. 700 μL of this cytokine-RPMI solution 
were added to each well and incubated for 48 hours to generate M2 macrophages. Figure 1 
depicts our strategy for polarization of THP-1 cells to the different macrophage subsets. 
 
Figure 1. Macrophage polarization procedure. 
 
Co-culture of breast cancer cells and macrophages 
After polarization of THP-1 cells to M2 macrophages, an equal number of MDA-MB-231 breast 
cancer cells were added to M2 macrophages in 24-well plates such that 500,000 breast cancer 
cells were placed in each well. Polarizing cytokines were also added to the wells at a 
concentration of 1 μL/mL of breast cancer cells added. Cells were allowed to incubate for 4 h 
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and then infected with rwt or rM51R-M virus for 24 hours. Supernatant was collected and stored 
at -80°C until use. For controls, M2 macrophages and MDA-MB-231 cells were infected alone, 
to determine the effect of the viral strains on cytokine levels in the absence of co-culture. 
Cytokine levels were determined with the use of ELISAs following the manufacturer’s protocol 
(BD OptEIA) and as outlined by Ahmed et al. (Ahmed, Puckett, Armilli, Braxton, Mizel and 
Lyes, 2010). The procedure for co-culture of breast cancer cells with macrophages is depicted in 
Figure 2.  
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Figure 2.  Co-culture of M2 macrophages and MDA-MB-231 breast cancer cells. 
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Determination of cell viability: 
1. Trypan Blue Exclusion: 
Cells were co-cultured as described previously in the methods. After co-culture, cells were lifted 
with Accutase. 10 µL of sample were combined with 10 µL of trypan blue dye and homogenized 
by pipetting up and down. 10 µL of this mixture was placed into a hemocytometer and the live 
and dead cells were counted. 
 
2. Cell tracker  
THP-1 cell staining with CellTracker Violet 
THP-1 cells were harvested by centrifugation and supernatants were aspirated. Cells were 
resuspended in pre-warmed CellTracker™ Working Solution and incubated for 15–45 minutes at 
37°C + 5% CO2. After centrifugation, labeled cells were removed from the CellTracker™ 
Working Solution, resuspended in RPMI + 10% FBS, and dispensed into a 6-well plate. Cells 
were imaged directly after staining using the 4′,6-diamidino-2-phenylindole(DAPI) excitation 
filter for the CellTracker™ Violet probe. 
 
MDA-MB-231s, M2 macrophages staining:  
Cells were cultured in a 6-well plate. After reaching 80% confluency, the culture media was 
removed. Pre-warmed CellTracker™ Working Solution was added to dish and incubated for 15–
45 minutes at 37°C + 5% CO2. CellTracker™ Working Solution was removed and 3 mL of 
RPMI+ 10 % FBS was added to each well. Plate was imaged using fluorescent microscopy with 
the 4′,6-diamidino-2-phenylindole (DAPI) excitation filter for the CellTracker™ Violet probe 
directly after labeling, then again 24 hours post-labeling.  
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RESULTS  
Il-6 production increases in co-culture conditions after infection with mutant VSV 
Previous studies in our laboratory have shown that M2 macrophages are susceptible to infection 
and killing by both rwt and rM51R-M viruses (Polzin, 2017). In addition, results suggest that 
infection of M2 macrophages by VSV educates the macrophages into a more M1-like 
macrophage phenotype (Polzin, 2017) as seen by the expression of cytokines and cell surface 
markers indicative of the M1 state. What is not known is how VSV impacts macrophages, as 
well as tumor cells, in the context of a tumor microenvironment. To determine whether oncolytic 
VSV has the ability to modulate macrophages and breast cancer cells in a simulated tumor 
microenvironment, THP-1 cells differentiated into M2 macrophages were co-cultured with 
MDA-MB-231 cells and infected with rwt and rM51R-M viruses at MOIs of 1 and 10 pfu/cell. 
An MOI of 1 indicates that each cell in culture will be exposed to one plaque-forming unit (pfu) 
or virus particle in the culture. However, in actuality, when infected at an MOI of 1, only 45-
65% of cells in culture will be infected with at least one virus particle. This method of infection 
allows us to observe how a virus replicates and spreads within a culture. An MOI of 10 indicates 
that 10 virus particles are added to a culture for each cell in that culture. With an MOI of 10, 
virtually 100% of the cells in the culture are infected. This method of infection allows us to 
observe how the cells respond to a synchronous infection with virus. Following infection for 24h, 
supernatants were collected and subjected to ELISA for the detection of secreted IL-6. M1-like 
macrophages are capable of producing IL-6 in response to exposure to endogenous pathogens, 
and thus, this cytokine serves as a marker for M1 macrophages. Figure 3A shows IL-6 levels 
induced by M2 macrophages alone and in direct co-culture with MDA-MB-231 breast cancer 
cells with and without infection with VSV.  Results showed that minimal IL-6 is produced by 
17 
 
M2 macrophages, and that neither rwt nor rM51R-M virus is capable of stimulating production 
of IL-6 by these macrophages. However, MDA-MB-231 cells produce higher levels of IL-6 on 
their own (Figure 3B) and neither virus alters those levels. Interestingly, when macrophages are 
co-cultured with breast cancer cells, overall levels of IL-6 decrease as compared to those 
produced by breast cancer cells alone. In addition, infection by rM51R-M virus elicits an 
increase in IL-6 production under co-culture conditions. These results indicate that infection with 
rM51R-M VSV could cause M2 macrophages to upregulate M1 markers, in this case IL-6, when 
these macrophages are co-cultured with MDA-MB-231 breast cancer cells. This suggests that the 
virus could be educating the M2 macrophages to a more M1-like phenotype in response to 
infection, such that they secrete IL-6 as an immune response to infection with the virus. The 
absence of an observable increase in IL-6 production by M2 macrophages alone when infected 
with mutant virus, compared to the significant increase observed in co-culture conditions after 
infection with mutant VSV suggests that the presence of cancer antigen could influence IL-6 
secretion by M2 macrophages. Indirect co-cultures with cancer antigen and M2 macrophages 
would elucidate the validity of this hypothesis. 
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Figure 3. IL-6 production by MDA-MB-231 cells, M2 Macrophages and Co-culture after 24 
hr infection with VSV. Production of IL-6 (pg/mL) by M2 macrophages and co-culture wells 
(A) and MDA-MB-231 cells (B) after infection with either rwt or rM51R-M viruses at an MOI 
of 1 or 10 pfu/cell for 24 hours. Data are the means and standard deviations of 3 independent 
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experiments. Cells in Figure A were grown in media without serum, while those in Figure B 
were grown in media with serum. 
 
TNF-α production by M2 macrophages alone increases after infection with rM51R-M virus  
Another cytokine that serves as a marker for M1 macrophages is TNF-α. TNF-α has been 
associated with enhancing the polarization towards M1 macrophages and inhibiting the M2 
phenotype.  As before, MDA-MB-231 cells were co-cultured with M2 macrophages and infected 
with VSV.  Secreted TNF-α was determined by ELISA at 24 h post-infection (Figure 4A). 
Results indicated that low levels of TNF-α were produced by M2 macrophages, as expected. 
However, rM51R-M virus significantly increased TNF-α levels when infected at both MOIs. In 
contrast, rwt virus did not stimulate TNF-α production in these cells.  MDA-MB-231 cells alone 
did produced higher levels of TNFa as compared to M2 macrophages and VSV did not induce 
changes in levels of this cytokine. Similar to results in figure 3 with IL-6, overall levels of TNFa 
decreased under co-culture conditions. However, under co-culture conditions, rM51R-M virus 
induced TNF-α production, but levels were lower than those obtained from M2 cells infected 
alone with rM51R-M virus. These data indicate that the breast cancer cells could potentially 
secrete factors that inhibit the production of TNF-α by M2 macrophages after infection with 
rM51R-M virus under co-culture conditions. These data also indicate that cells in co-culture 
could be more resistant to infection by rM51R-M than cells cultured alone. Further research is 
currently being conducted in our lab to determine whether or not this is the case. 
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Figure 4. TNF-α production by MDA-MB-231 cells, M2 Macrophages and Co-culture after 
24 hr infection with VSV. Production of TNF-ɑ (pg/mL) by M2 macrophages and co-culture 
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(A) wells and MDA-MB-231 cells grown in media without serum (B) after infection with either 
rwt or rM51R-M VSV at an MOI of 1 or 10 pfu/cell for 24 hours. Data are the means and 
standard deviations of 3 independent experiments. Cells in Figure A were grown in media 
without serum, while those in Figure B were grown in media with serum. 
 
Cells in co-culture are more resistant to cell death induced by VSV than cells cultured alone 
Previous work in our lab has shown that M2 macrophages and MDA-MB-231 cells alone are 
susceptible to infection and killing by VSV. What is not known is whether under co-culture 
conditions, cells remain susceptible to killing by VSV, or if they are resistant to VSV infection 
due to a ‘field-effect’ within the simulated tumor microenvironment. Furthermore, determination 
of the viability of cells within the microenvironment may provide insight into the mechanisms by 
which VSV modulates macrophage populations during oncolytic therapies. To start to determine 
how VSV impacts the viability of cells in the simulated tumor microenvironment, M2 
macrophages alone, and in co-culture with MDA-MB-231 cells were infected with rwt and 
rM51R-M viruses for 24h. Cells were harvested and exposed to trypan blue to determine cell 
viability. Figure 5 shows the percentage of surviving cells following VSV infection relative to 
those under mock-infection conditions.  
     Preliminary results from one experiment indicate that a greater number of M2 macrophages 
died after infection with rwt virus when compared to the cell death observed following infection 
with rM51R-M virus. This was the case when cells were infected at either MOI of 1 or 10 
pfu/cell. We also observed a decrease in cell viability in the co-culture wells after infection with 
rwt virus at both MOIs. Finally, our results showed that a decrease in cell death occurred in co-
culture conditions after infection with rM51R-M virus as indicated by an increase in viability as 
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compared to mock-infected cells. Although these studies do not distinguish how VSV affected 
individual cell populations (macrophage or breast cancer) within the co-culture, future studies 
are aimed at dissecting the response of specific cells within the simulated tumor 
microenvironment.  
 
 
Figure 5. The Effects of VSV on Viability of M2 macrophages and MDA-MB-231 breast 
cancer cells alone and in direct co-culture. Viability of total cells within the co-culture was 
tested through trypan blue exclusion. Data are expressed as the percentage of cell survival within 
the total cell populations (MDA-MB-231, M2 macrophages). Data shown represents one 
experiment. 
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MDA-MB-231 breast cancer cells are able to be labeled by CellTrackerTM Violet 
One means to determine how cells within the co-culture population are responding to infection 
with VSV, is by distinguishing cells within the co-culture through labeling and then measuring 
the impact of virus infection on specific populations. To do this, I attempted to label cells with 
CellTrackerTM violet. CellTrackerTM Violet is a fluorescent dye that can be used to stain living 
cells. It is retained in the membranes of cells for up 72 hours and through several generations. In 
order to properly stain the cells for fluorescent imaging, we first had to determine which cell type 
-THP-1's, M2 macrophages, or MDA-MB-231 breast cancer cells- would be the most 
appropriate for labeling. We first labeled THP-1 monocytes with the CellTrackerTM Violet at 
concentrations ranging from 0.5µM-3µM. When they were imaged, fluorescence could not be 
detected (data not shown). Upon further inspection, it was found that the dye was causing the 
cells to die at the higher of the concentrations. Therefore, higher concentrations of CellTrackerTM 
were not tested on this cell line. The MDA-MB-231 breast cancer cells were incubated in 
concentrations of cell tracker ranging from 3µM-5µM. Upon imaging, very dim fluorescence 
was observed (Figure 6), however the signal was not strong enough to track the cells in culture. 
Upon inspection, the cells looked healthy and did not show signs of stress due to the dye. Higher 
concentrations will be tested in the future to determine which concentration of CellTrackerTM 
dye is optimal for labeling the cells.  
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Figure 6. Labeling MDA-MB-231 breast cancer cells with various concentrations of 
CellTrackerTM Violet dye. Brightfield and fluorescent imaging of MDA-MB-231 breast cancer 
cells after incubation with various concentration of CellTrackerTM Violet. Cells were imaged 
immediately after incubation and 24 hours after incubation with dye. Fluorescence was imaged 
with 4′,6-diamidino-2-phenylindole (DAPI) filter.  
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DISCUSSION  
The results of this study have shown the ways by which rM51R-M vesicular stomatitis virus 
interacts with components of a simulated tumor microenvironment. One of the responses that 
elucidates VSV's interactions with TME components is cytokine secretion by these components 
after infection with virus. We observed increased IL-6 production in co-culture conditions 
infected with mutant VSV compared to those of untreated co-cultures. We also observed 
increased TNF-α production co-culture wells treated with rM51R-M virus over untreated co-
culture wells. Higher levels of IL-6 and TNF-α within the TME indicate that the environment is 
pro-inflammatory, while lower levels are an indication of an anti-inflammatory TME. An anti-
inflammatory TME encourages metastasis of the tumor, while a pro-inflammatory TME 
encourages suppression of tumor growth and inhibition of metastasis. The observable increase in 
pro-inflammatory cytokines in our co-culture wells after infection with mutant VSV indicates 
that mutant VSV has the potential to modulate the TME to a more pro-inflammatory state. This 
modulation to a pro-inflammatory state could potentially discourage metastasis, both at the 
primary tumor site and at distal sites with secondary tumors. Modulation of the TME from an 
anti-inflammatory state to a more pro-inflammatory state also suggests that M2 macrophages are 
undergoing a phenotypic switch to more M1-like macrophages after infection with rM51R-M 
virus, and are therefore producing pro-inflammatory cytokines as a result of this switch.  Other 
oncolytic viruses have been shown to potentially encourage a phenotypic switch in M2 
macrophages. One study found evidence that M2 macrophages display phenotypic alterations 
toward a more M1-like macrophage in co-culture with MDA-MB-231 breast cancer cells after 
infection with attenuated measles and mumps viruses (Tan et. al., 2016).   
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Previous research conducted in our lab suggests that M2 macrophages possess phenotypic 
plasticity, such that, upon exposure to virus, they have the ability to convert to a more M1-like 
state by upregulating M1 macrophage markers such as STAT1/pSTAT and downregulating 
pathways associated with M2 function, including CD204 expression. (Polzin, 2017). Under 
normal circumstances, M2 macrophages do not produce TNF-α as an effector cytokine. 
However, M1 macrophages do produce TNF-α as an effector cytokine once polarized to the M1 
phenotype. Our data indicates that M2 macrophages infected with rM51R-M virus produce 
significantly more TNF-α than those that were not infected. This supports the implication of the 
previous data, that M2 macrophages may switch to a more M1-like phenotype upon infection 
with mutant VSV (Polzin, 2017). This could be due to the virus's ability to induce a type I IFN 
response in cells that it infects. The inability of the M protein mutant VSV to inhibit the host 
cell's IFN response make the mutant virus uniquely qualified to encourage this phenotypic 
switching of M2 anti-inflammatory macrophages to a more pro-inflammatory M1-like 
macrophage. Further research is being conducted in our lab to determine whether or not this is 
the case. 
  
Looking at cell viability (Figure 5), there is more cell death from infection with rwt virus in both 
the M2 wells and the co-culture conditions when compared to that of rM51R-M virus. This 
suggests that rwt is more lethal to cells due to its ability to take over host transcription factors 
and inhibit protein synthesis, which is consistent with data from other studies (Ahmed et. al, 
2003). It is also clear that more cell death took place in the M2 wells compared to that in the co-
culture conditions. This suggests that the cells are more resistant to VSV when in co-culture 
conditions. This could be due to the M2's ability to encourage survival of cancer cells within the 
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tumor microenvironment. Cancer is a disease whose goal is to resist cell death and proliferate 
indeterminately. The M2s could be engaging in cytokine cross-talk with the cancer cells that 
would encourage the survival of the cancer cells and make them more resistant to infection with 
virus. However, this data is the product of only one experiment, so further research will be 
conducted to determine if this is the case.  
 
Our results showed that MDA-MB-231 breast cancer cells were more effectively labeled with 
the CellTrackerTM Violet than the THP-1 human monocytic cell line (data not shown). THP-1 
cells were incubated in concentrations of CellTrackerTM Violet ranging from 0.5 µM-3µM. 
When analyzed using fluorescent microscopy, the signal from the cells was too dim for all of the 
concentrations. Furthermore, upon inspection it was discovered that the THP-1's were being 
killed by the higher concentrations of the dye, so it was decided that the MDA-MB-231 breast 
cancer cells would be more effectively labeled.  
 
The optimal concentration for the CellTrackerTM Violet dye has not yet been determined. 
Concentrations of dye ranging from 3µM-5µM were tested, however the signal given off by the 
cells after incubation in these concentrations was not strong enough to produce a clear image. In 
the package directions, the highest recommended working concentration of dye is 25 µM. Our 
concentrations may simply not have been concentrated enough to induce a strong enough 
fluorescence in the cells. Further testing of higher concentrations will be performed to determine 
the optimal concentration of dye. 
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In conclusion, my results showed that mutant VSV is able to induce the secretion of pro-
inflammatory cytokines in co-culture conditions.  These results imply that the strength in using 
VSV as an oncolytic agent lies not only in its ability to directly kill cancer cells, but also 
manipulate macrophages within the tumor microenvironment. Therefore, it is important to 
further study the underlying mechanism of this phenomenon and better understand the 
implications this information has on the use of VSV an oncolytic agent. 
 
FUTURE DIRECTIONS 
An important step in elucidating the ways in which VSV interacts with the tumor 
microenvironment is determining how well VSV is able to infect M2 macrophages in co-culture 
conditions. Previous research in our lab suggests that M2 macrophages are sensitive to infection 
by VSV when cultured alone (Polzin, 2017), however their susceptibility to VSV in co-culture 
has not been determined. To continue to investigate this issue, we will label MDA-MB-231 
breast cancer cells with CellTrackerTM Violet, then co-culture them with M2 macrophages and 
infect cells with VSV that has been mutated to express green fluorescent protein (GFP). When 
cells are infected with the GFP VSV, they fluoresce GFP when imaged with fluorescent 
microscopy. Labeling MDA-MB-231 breast cancer cells will allow us to differentiate infected 
breast cancer cells from infected M2 macrophages and count them to determine the percent 
infected. 
 
Finally, we will want to investigate the affect that infection by rM51R-M virus has on the 
viability of the two cell types in co-culture conditions. VSV is an oncolytic virus, such that 
cancer cells burst after prolonged infection. This lysis releases cancer cell antigen into the tumor 
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microenvironment and can be picked up by immune cells in the TME. These immune cells can 
then present the antigen to other immune cells throughout the body, creating a systemic immune 
response to the cancer. Therefore, it is important to determine if the cancer is resistant to killing 
by VSV in a simulated TME. Future experiments will involve repeating these co-cultures after 
labeling one of the cell with a fluorescent probe and staining for viability after infection.  
  
30 
 
REFERENCES 
Ahmed, M., et al. “Ability of the Matrix Protein of Vesicular Stomatitis Virus To Suppress Beta 
Interferon Gene Expression Is Genetically Correlated with the Inhibition of Host RNA 
and Protein Synthesis.” Journal of Virology, vol. 77, no. 8, 2003, pp. 4646–4657., 
doi:10.1128/jvi.77.8.4646-4657.2003. 
 
Ahmed, M., et al. “Immune Response in the Absence of Neurovirulence in Mice Infected with M 
Protein Mutant Vesicular Stomatitis Virus.” Journal of Virology, vol. 82, no. 18, 2008, 
pp. 9273–9277., doi:10.1128/jvi.00915-08. 
 
Ahmed, M., Lyles, D., 1998. Effect of vesicular stomatitis virus matrix protein on transcription 
directed by host RNA polymerases I, II, and III. J. Virol. 72, 8413-8419.  
 
Ahmed, Maryam, et al. “Matrix Protein Mutant of Vesicular Stomatitis Virus Stimulates 
Maturation of Myeloid Dendritic Cells.” PubMed, Journal of Virology, 1 Mar. 2006, 
www.ncbi.nlm.nih.gov/pmc/articles/PMC1395366/. 
 
Balachandran, Siddharth, and Glen Barber. “Vesicular Stomatitis Virus (VSV) Therapy of 
Tumors.” IUBMB Life, vol. 50, no. 2, 2000, pp. 135–138., doi:10.1080/713803696 . 
 
Carswell, E. A., et al. “An Endotoxin-Induced Serum Factor That Causes Necrosis of 
Tumors.”Proceedings of the National Academy of Sciences, vol. 72, no. 9, 1975, pp. 
3666–3670., doi:10.1073/pnas.72.9.3666. 
31 
 
 
Chanmee, Theerawut, et al. “Tumor-Associated Macrophages as Major Players in the Tumor 
Microenvironment.” Cancers, vol. 6, no. 3, 2014, pp. 1670–1690., 
doi:10.3390/cancers6031670. 
 
Chung, Cathie T., and Robert W. Carlson. “Goals and Objectives in the Management of 
Metastatic Breast Cancer .” The Oncologist, 1 Dec. 2003, 
theoncologist.alphamedpress.org/content/8/6/514.long. 
 
Duque, Guillermo Arango, and Albert Descoteaux. “Macrophage Cytokines: Involvement in 
Immunity and Infectious Diseases.” Frontiers in Immunology, vol. 5, 2014, 
doi:10.3389/fimmu.2014.00491. 
 
Fukuhara, Hiroshi, et al. “Oncolytic Virus Therapy: A New Era of Cancer Treatment at 
Dawn.”Cancer Science, vol. 107, no. 10, 2016, pp. 1373–1379., doi:10.1111/cas.13027. 
 
Hastie, E., and V. Z. Grdzelishvili. “Vesicular Stomatitis Virus as a Flexible Platform for 
Oncolytic Virotherapy against Cancer.” Journal of General Virology, vol. 93, no. Pt_12, 
2012, pp. 2529–2545., doi:10.1099/vir.0.046672-0. 
 
Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced 
oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292–
303. 
32 
 
 
Lun, X. Q., et al. “Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for 
Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or 
Cyclophosphamide.” Clinical Cancer Research, vol. 15, no. 8, 2009, pp. 2777–2788., 
doi:10.1158/1078-0432.ccr-08-2342. 
 
O’Shaughnessy, Joyce. “Extending Survival with Chemotherapy in Metastatic Breast Cancer.” 
The Oncologist, 1 Oct. 2005, 
theoncologist.alphamedpress.org/content/10/suppl_3/20.short. 
 
Ottolino-Perry, Kathryn, et al. “Intelligent Design: Combination Therapy With Oncolytic 
Viruses.” Molecular Therapy, vol. 18, no. 2, 2010, pp. 251–263., 
doi:10.1038/mt.2009.283. 
 
Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD., and Martuza RL. Oncolytic 
herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer 
cells. Cancer Gene Ther. 2009;16:551–560. 
 
Racaniello, Vincent. “Multiplicity of Infection.” Virology Blog, 20 Jan. 2011, 
www.virology.ws/2011/01/13/multiplicity-of-infection/. 
 
33 
 
Raggi, Federica, et al. “Regulation of Human Macrophage M1–M2 Polarization Balance by 
Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1.” Frontiers, 7 Sept. 
2017, www.frontiersin.org/articles/10.3389/fimmu.2017.01097/full.  
 
Rehman, Hasan, et al. “Into the Clinic: Talimogene Laherparepvec (T-VEC), a First-in-Class 
Intratumoral Oncolytic Viral Therapy.” Journal for ImmunoTherapy of Cancer, BioMed 
Central, 20 Sept. 2016, jitc.biomedcentral.com/articles/10.1186/s40425-016-0158-5. 
 
Russell, Stephen J., and Kah-Whye Peng. “Viruses as Anticancer Drugs.” Trends in 
Pharmacological Sciences, vol. 28, no. 7, 18 June 2007, pp. 326–333., 
doi:10.1016/j.tips.2007.05.005. 
 
Seyfried, T.N., Huysentruyt, L.C., 2013. On the origin of cancer metastasis. Crit. Rev. 
Oncog. 18, 43–73. 
 
Stojdl, David F, et al. “VSV Strains with Defects in Their Ability to Shutdown Innate Immunity 
Are Potent Systemic Anti-Cancer Agents.” Cancer Cell, vol. 4, no. 4, Oct. 2003, pp. 263–
275., doi:10.1016/s1535-6108(03)00241-1. 
 
Tan, Darren Qiancheng, et al. “Macrophage Response to Oncolytic Paramyxoviruses Potentiates 
Virus-Mediated Tumor Cell Killing.” European Journal of Immunology, vol. 46, no. 4, 
2016, pp. 919–928., doi:10.1002/eji.201545915. 
 
34 
 
Yu, W, and H Fang. “Clinical Trials with Oncolytic Adenovirus in China.” CiteSeerX, U.S. 
National Library of Medicine, Mar. 2007, www.ncbi.nlm.nih.gov/pubmed/17346105. 
